The javascript used on this site for creative design effects is not supported by your browser. Please note that this will not affect access to the content on this web site.

HAART was approved by the FDA in 1995 because and becomes widely available 1 year later.1

Other News In 1995

For women, transmission of HIV through heterosexual contact rises by 38 percent, equal to the number of women who contract HIV by injection drug use.2

Researchers discover that the HIV virus is highly susceptible to mutation and likely to result in resistance to antiviral therapies.3

Olympic gold medalist Greg Louganis announces he is HIV positive, leading to public debate on disclosure.4


First Protease Inhibitor Becomes Available

In a development that would forever change the HIV/AIDS treatment landscape, the FDA approved an open label study of saquinavir in June 1995. The first drug of its kind to be made available outside ongoing clinical trials, saquinavir is a protease inhibitor. It targets a cell’s protease, which is a protein needed by HIV to replicate itself.

On December 6, 1995, just 6 months later—virtually a nanosecond on a typical drug approval timeline—saquinavir was approved for use in combination with other nucleoside analogue medications. The age of combination therapy—and a new era of hope for people with access to the new treatment—had arrived.

The news media referred to the new treatment variously as a “drug cocktail,” “triple combination therapy,” “combination therapy,” “antiretroviral therapy” and, often, simply as “protease inhibitors.” Among scientists, the use of drugs (usually two) in combination with a protease inhibitor was called highly active antiretroviral therapy, or HAART.

HAART became widely available to people living with HIV/AIDS in 1996. AIDS morbidity and mortality fell almost immediately in the industrialized world, and the way we think about AIDS also changed forever.

Skip to credits